Eltrombopag olamine and Thirst - a phase IV clinical study of FDA data

Summary:

Thirst is reported as a side effect among people who take Eltrombopag olamine (eltrombopag olamine), especially for people who are female, 60+ old, also take Mycophenolate Mofetil, and have Thyroid diseases.

The phase IV clinical study analyzes which people have Thirst when taking Eltrombopag olamine. It is created by eHealthMe based on reports of 3,901 people who have side effects when taking Eltrombopag olamine from the FDA, and is updated regularly.

What is Eltrombopag olamine?

Eltrombopag olamine has active ingredients of eltrombopag olamine. eHealthMe is studying from 3,901 Eltrombopag olamine users. Check the latest studies of Eltrombopag olamine.

What is Thirst?

Thirst is found to be associated with 1,170 drugs and 1,324 conditions by eHealthMe. Check the latest studies of Thirst.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

3,901 people reported to have side effects when taking Eltrombopag olamine.
Among them, 11 people (0.28%) have Thirst.

Among these 11 people:

What is the gender of people who have Thirst when taking Eltrombopag olamine? *

female: 90.91 %
male: 9.09 %

What is the age of people who have Thirst when taking Eltrombopag olamine? *

What are other drugs people take besides Eltrombopag olamine? *

What are other side effects people have besides Thirst? *

Thrombocytopenia (decrease of platelets in blood): 11 people, 100.00%
Fatigue (feeling of tiredness): 9 people, 81.82%
Stress And Anxiety: 9 people, 81.82%
Dry Mouth: 8 people, 72.73%
Haematoma (collection of blood outside the blood vessels): 8 people, 72.73%
Systemic Lupus Erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue): 8 people, 72.73%
Glaucoma (increased fluid pressure in the eye with vision loss): 7 people, 63.64%
Drug Intolerance (drug sensitivity): 7 people, 63.64%
Foaming At Mouth (excess saliva secretion): 7 people, 63.64%
Hyperhidrosis (abnormally increased sweating): 7 people, 63.64%

What are the existing conditions these people have? *

Thyroid Diseases: 7 people, 63.64%
Thrombocytopenia (decrease of platelets in blood): 2 people, 18.18%
Hypercoagulation (increased tendency for clotting of the blood): 2 people, 18.18%
Purpura (purplish discoloration of the skin): 1 person, 9.09%
High Blood Pressure: 1 person, 9.09%
High Blood Cholesterol: 1 person, 9.09%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Eltrombopag olamine and have Thirst?

- Check whether Thirst is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Eltrombopag olamine:

Eltrombopag olamine (3,901 reports)

Thirst treatments and more:

Thirst (21,000 reports)

Browse all side effects of Eltrombopag olamine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Thirst:

Thirst (1,170 drugs)

Browse all the conditions that are associated with Thirst:

Thirst (1,324 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on eltrombopag olamine (the active ingredients of Eltrombopag olamine) and Eltrombopag olamine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.